Monotherapy for Rheumatoid Arthritis: Leveraging the Latest Evidence to Treat to Target

In this interactive, CME/CE/CPE-certified video module, Jonathan Scott Coblyn, MD; Jessica Farrell, PharmD; and Frances Griffin, RN, BSN, provide multidisciplinary perspectives on best practices in the use of traditional, biologic, and targeted synthetic DMARD monotherapy to treat rheumatoid arthritis.
Jonathan Scott Coblyn, MD
Program Director
Jessica Farrell, PharmD
Frances Griffin, RN, BSN
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: June 29, 2018 Expiration: June 28, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Use the latest guideline recommendations to determine a course of action for patients with active RA in order to achieve therapeutic targets
  • Apply the clinical study and real-world evidence for biologic and targeted synthetic DMARD monotherapy when making decisions about drug regimens for patients with RA
  • Collaborate with various disciplines to engage patients and to optimize RA treatment and patient functioning

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Jonathan Scott Coblyn, MD

Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director of Rheumatology
Division of Rheumatology
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Jonathan Scott Coblyn, MD, has no real or apparent conflicts of interest to report.

Faculty

Jessica Farrell, PharmD

Associate Professor
Department of Pharmacy Practice
Albany College of Pharmacy & Health Sciences
Clinical Pharmacist
The Center for Rheumatology
Albany, New York

Jessica Farrell, PharmD, has no real or apparent conflicts of interest to report.
Frances Griffin, RN, BSN

Staff Nurse
Department of Rheumatology
Brigham & Women's Hospital
Registered Nurse
Brigham & Women's Hospital Arthritis Center
Boston, Massachusetts

Frances Griffin, RN, BSN, has no real or apparent conflicts of interest to report.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jayoo Gokhale

Editorial Contributor

Jayoo Gokhale has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, registered nurses, physician assistants, occupational therapists, pharmacists, social workers, and all other healthcare professionals involved in the care of adult patients with RA.

Goal

The goal of this activity is to improve participants’ competence in applying a multidisciplinary approach to achieving therapeutic targets with DMARD monotherapy in patients with active RA.

Physician Continuing Medical Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options. LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

 Pharmacist Continuing Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-18-261-H01-P)

Type of Activity: Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 29, 2018, through June 28, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expired: January 8, 2021

CCO faculty Dr. Stanley Cohen’s viewpoint on data from 2019 ACR/ARP on investigational and approved JAK inhibitors for RA

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 5, 2019 Expired: December 4, 2020

7-year baricitinib safety data in RA patients consistent with earlier reports and acceptable considering efficacy from 2019 ACR, as reported by CCO; safety evaluations ongoing

Released: November 25, 2019

Latest data on IRAK4 inhibitor PF-06650833 in moderately to severely active RA presented at ACR/ARHP 2019 as reported by Clinical Care Options (CCO)

Released: November 18, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?